T Cell News and Research

Latest T Cell News and Research

Scientists work towards creating a vaccine for Parkinson's disease

Nina Brown, 68, and millions of others with a debilitating neurological condition called Parkinson's disease are counting on researchers for a cure. At The University of Texas Health Science Center at Houston (UTHealth), protein chemists are working to develop a therapeutic vaccine.

10 Aug 2010

Scientist develops nano-methods to destroy tumors with fewer side effects

Though a valuable weapon against cancerous tumors, radiation therapy often harms healthy tissue as it tries to kill malignant cells. Now, Prof. Israel Gannot of Tel Aviv University's Department of Biomedical Engineering is developing a new way to destroy tumors with fewer side effects and minimal damage to surrounding tissue.

10 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Scientists as well as fertility doctors have long tried to figure out what makes a good egg that will produce a healthy embryo. It's a particularly critical question for fertility doctors deciding which eggs isolated from a woman will produce the best embryos and, ultimately, babies.New research reveals healthy eggs need a tremendous amount of zinc to reach maturity and be ready for fertilization,a finding that may ultimately help physicians assess the best eggs for fertility treatment, according to a study from Northwestern University.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

New familial link in juvenile myelomonocytic leukemia discovered

A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.

9 Aug 2010

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food & Drug Administration (FDA).

9 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. These findings provide hope that it may be possible to design therapies for paralysis and other impairments of motor function arising from spinal cord injury.

9 Aug 2010

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

9 Aug 2010

Opexa Therapeutics aims to complete planned experiments, develop clinical study protocols

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2010 and provided an update on its corporate developments.

7 Aug 2010

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Shlomo Melmed, M.D., senior vice president for academic affairs and dean of the medical faculty at Cedars-Sinai Medical Center, has been appointed by Gov. Arnold Schwarzenegger to the Independent Citizen's Oversight Committee, the governing board of the California Institute for Regenerative Medicine.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

FDA seeks ban on Regenerative Sciences for violating cGMP

The U.S. Food and Drug Administration is seeking an injunction in federal court against Regenerative Sciences LLC, of Broomfield, Colo., citing violations of current good manufacturing practice (cGMP) that cause its cultured cell product to be adulterated. The product is also misbranded due to the lack of adequate directions for use and the failure to bear the "Rx only" symbol.

7 Aug 2010

Cyclacel second-quarter net loss decreases to $6.5 million

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.

7 Aug 2010

UCSF researchers discover new technology purifying special types of stem cells

UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.

7 Aug 2010

T Cell News and Research

Latest T Cell News and Research

Scientists work towards creating a vaccine for Parkinson's disease

Scientist develops nano-methods to destroy tumors with fewer side effects

Athersys second-quarter revenues increase to $1.9 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

New familial link in juvenile myelomonocytic leukemia discovered

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

ESMO Congress provides forum for presentation of new research on treatment of cancer

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Opexa Therapeutics aims to complete planned experiments, develop clinical study protocols

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

FDA seeks ban on Regenerative Sciences for violating cGMP

Cyclacel second-quarter net loss decreases to $6.5 million

UCSF researchers discover new technology purifying special types of stem cells

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in